Showing 9211-9220 of 19239 results for "".
- New Data Show BMI Influences Psoriasis Severity and Systemic Inflammationhttps://reachmd.com/news/new-data-show-bmi-influences-psoriasis-severity-and-systemic-inflammation/2485411/Obesity and overweight status were associated with higher baseline prevalence of cardiometabolic comorbidities, psoriatic arthritis (PsA), and systemic inflammation compared to individuals with normal BMI, according to new data from a poster at 2026 Winter Clinical
- Exploring Novel Epigenetic Inhibitors in Non-Small Cell Lung Cancerhttps://reachmd.com/news/novel-epigenetic-inhibitors-nsclc/2485389/Chemists at The University of Hong Kong report the development of an ATAC complex inhibitor that targets epigenetic drivers of non-small cel
- Genetic and Nutritional Insights: A New Frontier in Gut Motility and Inflammatory Bowel Diseasehttps://reachmd.com/news/genetic-and-nutritional-insights-a-new-frontier-in-gut-motility-and-inflammatory-bowel-disease/2485386/A genome-wide association study (GWAS) links 21 genomic regions to bowel-movement frequency and implicates vitamin B1 (thiamine)–related transport and metabolic pathways a
- FDA Grants Nanotechnology Designation to Curiteva’s 3D-Printed PEEK Spinal Implantshttps://reachmd.com/news/fda-grants-nanotechnology-designation-to-curitevas-3d-printed-peek-spinal-implants/2485392/Curiteva has received a nanotechnology designation from the U.S. Food and Drug Administration (FDA) for its Inspire 3D Printed Trabecu
- Interferon Responses in Rhinovirus: Implications for Pulmonary Practicehttps://reachmd.com/news/interferon-responses-in-rhinovirus-implications-for-pulmonary-practice/2485365/New nasal-epithelium data show that interferon response determines rhinovirus outcomes—shaping symptom burden a
- No New Safety Signals in Broad Ruxolitinib Dataset, Including AD, Vitiligo, and AAhttps://reachmd.com/news/no-new-safety-signals-in-broad-ruxolitinib-dataset-including-ad-vitiligo-and-aa/2485382/A new safety analysis presented at the 2026 Winter Clinical Dermatology Conference in Maui supporting the long-term tolerability of ruxolitinib cream (Opzelura®, Incyte) in a range of inflammatory skin conditions. The integrat
- Understanding Emotional Expressions in Autism: Clinical Implications and Strategieshttps://reachmd.com/news/understanding-emotional-expressions-in-autism-clinical-implications-and-strategies/2485370/Contrary to the longstanding assumption that basic emotions map onto universal facial markers, a comparative study of autistic and non-autistic adults identified divergent kinematic
- Innovations in Crohn's Disease Treatment: Harnessing Genetic Insightshttps://reachmd.com/news/crohns-disease-treatment-genetic-insights/2485376/Researchers at the Broad Institute have reported preclinical small-molecule modulators intended to phen
- Study: Upadacitinib Reduces Inflammation Markers in ADhttps://reachmd.com/news/study-upadacitinib-reduces-inflammation-markers-in-ad/2485380/Upadacitinib (UPA) treatment was associated with significant reductions in biomarkers of systemic inflammation in adults with moderate-to-severe atopic dermatitis (AD), according to a poster presented at Winter Clinical 2026 in Hawaii.
- TYK2 Inhibitor Envudeucitinib Shows Durable Skin Clearance, QoL Gains: Posterhttps://reachmd.com/news/tyk2-inhibitor-envudeucitinib-shows-durable-skin-clearance-qol-gains-poster/2485378/Envudeucitinib, an investigational selective allosteric TYK2 inhibitor, showed sustained achievement of clinically meaningful treat-to-target outcomes in patients with moderate-to-severe plaque psoriasis, according to 52-week data presented at 2026 Winter Clinical